Comparative Pharmacology
Head-to-head clinical analysis: CEDAX versus KEFLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEDAX versus KEFLEX.
CEDAX vs KEFLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftibuten is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP 3, thereby inhibiting peptidoglycan cross-linking and leading to cell lysis.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
400 mg orally once daily for 5-10 days.
250-500 mg orally every 6 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life: 2.6-3.0 hours; prolonged in renal impairment (up to 10-15 hours in severe impairment)
0.5–1.2 hours in patients with normal renal function (CrCl >50 mL/min); prolonged to >20 hours in ESRD.
Renal: 92-96% unchanged; biliary/fecal: <5%
Primarily renal (90% or more unchanged via glomerular filtration and tubular secretion); small amounts biliary/fecal (<5%).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic